Arcturus Therapeutics
ARCT
135 hedge funds and large institutions have $168M invested in Arcturus Therapeutics in 2026 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 56 increasing their positions, 40 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
40% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 40
9% more funds holding
Funds holding: 124 → 135 (+11)
2.44% more ownership
Funds ownership: 85.46% → 87.9% (+2.4%)
10% less capital invested
Capital invested by funds: $187M → $168M (-$19.4M)
33% less call options, than puts
Call options by funds: $207K | Put options by funds: $310K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$4.05M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.54M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.32M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.11M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$2.59M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$2.57M |
| 3 |
Renaissance Technologies
New York
|
-$1.24M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.23M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.17M |
ARCT Hedge Fund Activity: Q2 2026 in Review
135 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2026, worth a combined $168M — down 10% from $187M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ARCT positions and 8 closed out — a net gain of 12 holders — while 56 added to existing stakes and 40 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $4.05M. The largest seller was Nikko Asset Management Americas, cutting an estimated $2.59M.
- 135 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2026, up from 124 in Q1 2026.
- Funds reported $168M of Arcturus Therapeutics stock for Q2 2026, down 10% quarter-over-quarter.
- 20 funds opened new Arcturus Therapeutics positions in Q2 2026 and 8 closed out, a net change of +12 holders.
- The largest Arcturus Therapeutics buyer in Q2 2026 was AQR Capital Management, an estimated $4.05M added.
- The largest Arcturus Therapeutics seller in Q2 2026 was Nikko Asset Management Americas, an estimated $2.59M sold.
Based on aggregated 13F filings for Q2 2026.